Consolidated revenue for the third quarter of the fiscal year ending March 2026 was JPY 619.9 billion (3.1% increase YoY), operating income was JPY 54.5 billion (1.7% decrease YoY), and net income attributable to owners of parent for the quarter was JPY 41.8 billion (8.1% decrease YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4523-20260209-01.pdf","jir_short_summary":"Consolidated revenue for the third quarter of the fiscal year ending March 2026 was JPY 619.9 billion (3.1% increase YoY), operating income was JPY 54.5 billion (1.7% decrease YoY), and net income attributable to owners of parent for the quarter was JPY 41.8 billion (8.1% decrease YoY).","jir_summary":"### Overview of Financial Results\nFor the third quarter of the fiscal year ending March 2026, consolidated revenue increased by 3.1% YoY to JPY 619.9 billion, mainly driven by sales growth of the Alzheimer\u2019s disease treatment 'LEQEMBI,' the anticancer agent 'LENVIMA,' and the insomnia treatment 'Dayvigo.' Meanwhile, operating income declined by 1.7% YoY to JPY 54.5 billion, and net income attributable to owners of parent for the quarter decreased by 8.1% YoY to JPY 41.8 billion. Research and development expenses decreased due to continued resource allocation to key projects and efficiency improvements, while selling, general and administrative expenses increased due to aggressive investments in 'LENVIMA.' Other income decreased due to the absence of one-time gains recorded in the same period last year.\n\n### Segment Performance and Future Outlook\nThe pharmaceutical business operates in five regions: Japan, Americas, China, EMEA, and East Asia & Global South, with revenue growth achieved across all regions. Particularly, 'LEQEMBI' showed strong growth in each region, and in the United States, the subcutaneous auto-injector formulation 'LEQEMBI IQLIK' was newly launched. In China, multiple new product launches contributed to sales expansion. There is no revision to the full-year earnings forecast for the fiscal year ending March 2026, and an annual dividend of JPY 160 per share is planned. Going forward, the company will continue to promote research and development and partnerships, aiming to expand its business mainly in the dementia field.","jir_financial_highlights":"Revenue: JPY 619.9 billion (3.1% increase YoY)\nOperating Income: JPY 54.5 billion (1.7% decrease YoY)\nNet Income Attributable to Owners of Parent: JPY 41.8 billion (8.1% decrease YoY)\nAnnual Dividend (Forecast): JPY 160 (per share) (Same as previous fiscal year)\nNumber of Shares Issued (End of Period): 291,649,149 shares (Same as previous fiscal year-end)\nNumber of Treasury Shares (End of Period): 9,534,768 shares (Approximately the same as previous fiscal year-end)","jir_category":"","jir_hashtags":"#Eisai, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 619.9 billion (3.1% increase YoY)\nOperating Income: JPY 54.5 billion (1.7% decrease YoY)\nNet Income Attributable to Owners of Parent: JPY 41.8 billion (8.1% decrease YoY)","jir_meta_title":"Eisai Co., Ltd. Financial Summary for Q3 FY2026 Revenue Increases 3.1% to JPY 619.9 Billion","jir_meta_description":"Eisai Co., Ltd.'s financial summary for the third quarter of fiscal year ending March 2026. Revenue increased 3.1% YoY to JPY 619.9 billion, operating income decreased 1.7% to JPY 54.5 billion, and net income attributable to owners of parent fell 8.1% to JPY 41.8 billion. Annual dividend is planned at JPY 160 per share.","jir_og_title":"Eisai Financial Summary Q3 FY2026 Revenue Growth Amid Profit Decline","jir_og_description":"Eisai Co., Ltd.'s third quarter financial summary. Revenue reached JPY 619.9 billion (3.1% increase YoY), and operating income was JPY 54.5 billion (1.7% decrease YoY).","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (JPY Billion)\\\",\\\"data\\\":[6011.64,6199.50],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (JPY Billion)\\\",\\\"data\\\":[554.02,544.52],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (JPY Billion)\\\",\\\"data\\\":[454.84,418.08],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Pharmaceutical Business Segment Revenue (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Americas\\\",\\\"China\\\",\\\"EMEA\\\",\\\"East Asia & Global South\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (JPY Billion)\\\",\\\"data\\\":[1756,2230,998,603,514],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#3cba9f\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Annual Dividend Trend (JPY\/Share)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend\\\",\\\"data\\\":[160,160],\\\"backgroundColor\\\":\\\"#3cba9f\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26041","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n